High-risk individuals’ perceptions of reproductive genetic testing for CDH1 mutations

Nina Hallowell, Shirlene Badger, Sue Richardson, Carlos Caldas, Richard H. Hardwick, Rebecca C. Fitzgerald, Julia Lawton

Research output: Contribution to journalArticlepeer-review


Reproductive genetic testing- PreNatal Diagnosis (PND) and Preimplantation Genetic Diagnosis (PGD)—for CDH1 mutations associated with Hereditary Diffuse Gastric Cancer (HDGC)is available in the UK. This qualitative interview study examined high-risk individuals’ (n = 35) views of CDH1 reproductive genetic testing. Interviewees generally regarded reproductive genetic testing as an acceptable form of HDGC risk management. However, some were concerned that their genetic risks required them to plan reproduction and anticipated difficulties communicating this to reproductive partners. Individuals had a preference for PGD over PND because it avoided the need for a termination of pregnancy. However, those who had not yet had children expressed concerns about having to undergo IVF procedures and worries about their effectiveness and the need for embryo selection in PGD. It is suggested that high-risk individuals are provided with access to reproductive genetic counselling.
Original languageEnglish
JournalFamilial Cancer
Publication statusPublished - 15 Feb 2017


  • Hereditary diffuse gastric cancer
  • Preimplantation genetic diagnosis
  • Prenatal Diagnosis
  • E-cadherin
  • reproductive genetic testing
  • Hereditary Cancer


Dive into the research topics of 'High-risk individuals’ perceptions of reproductive genetic testing for CDH1 mutations'. Together they form a unique fingerprint.

Cite this